.jpg "Roth Capital Remains a Hold on Titan Pharmaceuticals")
Roth Capital analyst Scott Henry reiterated a Hold rating on Titan Pharmaceuticals (NASDAQ: TTNP) on May 18 and set a price target of $1.50. The company’s shares closed on Friday at $0.78, close to its 52-week low of $0.60.
According to TipRanks.com, Henry is a 4-star analyst with an average return of 4.1% and a 45.3% success rate. Henry covers the Healthcare sector, focusing on stocks such as Restoration Robotics Inc, Viking Therapeutics, and Natus Medical Inc.
Titan Pharmaceuticals has an analyst consensus of Hold, with a price target consensus of $1.50.
See today’s analyst top recommended stocks >>
Based on Titan Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $2.61 million. In comparison, last year the company had a GAAP net loss of $3.01 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Titan Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in developing proprietary therapeutics primarily for the treatment of medical disorders. Its products include Probuphine, provides non fluctuating blood levels of buprenorphine; Ropinirole implant, which provides dopaminergic stimulation; and T3 implant, which is used in hypothyroidism treatment. Its products are subdermal implants, which utilizes ProNeura drug delivery platform. The company was founded by Louis R. Bucalo in February 7, 1992 and is headquartered in South San Francisco, CA.
Read More on TTNP:
